Welcome to our dedicated page for Genprex news (Ticker: GNPX), a resource for investors and traders seeking the latest updates and insights on Genprex stock.
Genprex, Inc. develops clinical-stage gene therapies for cancer and diabetes, with recurring updates centered on Reqorsa® Gene Therapy (quaratusugene ozeplasmid) and its diabetes gene therapy candidate Pdx1/MafA, also referred to as GPX-002. Reqorsa uses a non-viral, lipid-based nanoparticle delivery approach for a TUSC2 gene-expressing plasmid and is being developed with approved cancer drugs for non-small cell lung cancer and small cell lung cancer.
Company news commonly covers patent grants and licensed intellectual property for Reqorsa combinations with PD-1 and PD-L1 antibodies, biomarker research involving TROP2 and PTEN, preclinical and clinical data presentations, sponsored research with UT MD Anderson, oncology trial references such as Acclaim-1 and Acclaim-3, diabetes preclinical research, industry conference participation and Nasdaq compliance updates.
Genprex (GNPX) will present at the H.C. Wainwright 28th Annual Global Investment Conference in New York City from September 14–16, 2026.
President and CEO Ryan Confer will give an overview of Reqorsa® Gene Therapy, the company’s lead clinical oncology candidate, and its preclinical diabetes program, including development priorities. Chief Medical Officer Mark Berger, MD, and Senior Vice President of Intellectual Property and Licensing Thomas Gallagher will attend and participate in one-on-one investor meetings.
Reqorsa (quaratusugene ozeplasmid) uses the systemic, non-viral ONCOPREX® Delivery System to deliver the TUSC2 tumor suppressor gene and is being evaluated in the Acclaim-1 and Acclaim-3 trials for non-small cell and small cell lung cancer, which have FDA Fast Track designations and an Orphan Drug designation for small cell lung cancer.
Genprex (NASDAQ:GNPX) announced a development and manufacturing agreement with a leading U.S.-based clinical and commercial CDMO to scale up manufacturing of its AAV-based diabetes gene therapy program. The CDMO will produce cGMP-compliant drug product for Genprex’s IND-enabling preclinical studies and planned future clinical trials.
The roadmap includes process optimization using advanced AAV technologies, bioreactor scale-up, analytical qualification and potency assay development, and strict GMP compliance. Genprex’s candidate delivers Pdx1 and MafA genes to the pancreas, aiming to convert alpha cells into insulin-producing beta-like cells in T1D and rejuvenate exhausted beta cells in T2D, with supporting mouse and NHP preclinical data.
Genprex (NASDAQ: GNPX) announced a collaboration with Roche Diagnostics to validate biomarker assays for patient selection in non-small cell lung cancer (NSCLC) clinical trials. The work focuses on using TROP2 as a biomarker, informed by Genprex data linking high TROP2 and low PTEN H-scores to improved Progression Free Survival (PFS) in NSCLC patients.
According to Genprex, Roche Diagnostics, which received FDA Breakthrough Device Designation for an AI-driven TROP2 companion diagnostic, will perform assay validation using its established TROP2 antibody. Genprex plans to complete validation studies by approximately the end of 2026 and then seek to integrate TROP2-based patient selection into its NSCLC clinical program, depending on validation results. The collaboration is intended to support more precise enrollment in studies of Genprex’s lead product candidate, Reqorsa Gene Therapy, and advance biomarker-driven precision medicine in oncology.
Genprex (NASDAQ:GNPX) received a Notice of Allowance from the Canadian Intellectual Property Office for a patent covering Reqorsa gene therapy combined with PD-1 or PD-L1 antibodies to treat NSCLC and SCLC. The patent covers combinations used in the Acclaim-3 trial with Tecentriq and expands Genprex's global IP portfolio.
Genprex (NASDAQ:GNPX), a clinical-stage gene therapy company developing treatments for cancer and diabetes, will attend the BIO 2026 International Convention in San Diego from June 22-25, 2026.
Senior Vice President Thomas Gallagher will hold in-person one-on-one meetings about Genprex's gene therapy programs.
Genprex (NASDAQ:GNPX) reported positive biomarker data for its Reqorsa gene therapy (quaratusugene ozeplasmid) presented at the 2026 ASCO Annual Meeting.
In 18 lung cancer patients, higher Trop-2 H-scores (>100) and lower PTEN H-scores (<100) correlated with longer progression-free survival in NSCLC, but not in SCLC. Additional intensity staining analyses suggested a strong, though not statistically significant, relationship between high (3+) Trop-2 expression and PFS.
Genprex (NASDAQ:GNPX) reported positive preclinical data for its diabetes gene therapy candidate Pdx1/MafA (PM, GPX-002) in Type 2 diabetes mouse models, presented at the 2026 ASGCT Annual Meeting.
Pancreatic AAV-Pdx1/MafA delivery reversed hyperglycemia within four weeks and improved β-cell function, insulin secretion, and maturation markers in high-fat-diet mice.
Genprex (NASDAQ: GNPX) announced that the Israel Patent Office granted a patent covering the use of Reqorsa® (quaratusugene ozeplasmid) in combination with PD-1 antibodies to treat cancer.
The patent expands protection for Reqorsa® in Israel and complements previously granted combination patents in the U.S., Japan, Mexico, Russia, Australia, Chile, China, Singapore and Europe. Reqorsa is being developed initially in combination with approved cancer drugs for lung cancer and has shown complementary activity with targeted drugs and immunotherapies in preclinical studies.
Genprex (NASDAQ: GNPX) collaborators will present positive preclinical data showing the Pdx1/MafA (PM, GPX-002) gene therapy reversed HFD-induced hyperglycemia in Type 2 diabetic mouse models with complete rescue by four weeks after intrapancreatic AAV-8 delivery. CMV and RIP promoter constructs improved ex-vivo glucose-stimulated insulin secretion to levels similar to regular-diet controls. Electron microscopy showed more mature insulin granules and transcriptomic analysis indicated β-cell maturation. The poster (ASGCT 2026, Abstract 2419) is scheduled for May 13, 2026; the team notes technical translatability to humans via endoscopic retrograde cholangiopancreatography.
Genprex (NASDAQ:GNPX) announced that a research collaborator's abstract reporting positive clinical biomarker data for Reqorsa® Gene Therapy (quaratusugene ozeplasmid) was selected for publication at the 2026 ASCO Annual Meeting, May 29–June 2, 2026 in Chicago.
The abstract (e15184) describes predictive biomarkers for progression‑free survival (PFS) in patients receiving Reqorsa, which the company says may help enrich lung cancer trials and predict patient response.